Importantly, cancer risk is not uniform: carriers of MLH1 and MSH2 variants generally face higher lifetime risk and penetrance than those with MSH6 or PMS2 variants, enabling gene-specific counseling and surveillance recommendations. This evidence concerns the gene MSH6 and cancer.